Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Stock Information for AnaptysBio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AnaptysBio Inc.

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB)
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AnaptysBio, Inc. - ANAB
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTI Surgical, AnaptysBio, Hanmi Financial, and HF Foods Group and Encourages Investors to Contact the Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.